Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00230399
Status:
COMPLETED
Last Update Posted:
2015-04-21
First Post:
2005-09-09
Brief Title:
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
University of Michigan Rogel Cancer Center
Study Overview
Official Title:
C-2424 Phase II Study of Celecoxib Capecitabine and Irinotecan in Patients With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine a new combination of drugs celecoxib capecitabine and irinotecan for the treatment of metastatic colorectal cancer Capecitabine and irinotecan individually are approved by the Food and Drug Administration FDA for use in colorectal cancer The combination of these two drugs is experimental not approved by the FDA as standard treatment but is a widely used treatment option and preliminary studies have shown that treatment with the combination of capecitabine and irinotecan has a positive effect on metastatic colorectal cancer Likewise previous research in animals has shown that celecoxib a drug approved for arthritis therapy also has activity against this tumor type and may improve the anti-cancer activity of the combination of capecitabine and irinotecan
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None